Roivant Sciences Ltd (ROIV) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Roivant Sciences Ltd (ROIV) has a cash flow conversion efficiency ratio of -0.040x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-196.48 Million) by net assets ($4.97 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see market value of Roivant Sciences Ltd for the company's overall valuation and market capitalisation.
Roivant Sciences Ltd - Cash Flow Conversion Efficiency Trend (2019–2025)
This chart illustrates how Roivant Sciences Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Roivant Sciences Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Roivant Sciences Ltd ranked by their cash flow conversion efficiency. Explore Roivant Sciences Ltd earnings quality ratio to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
NN Group NV
AS:NN
|
-0.057x |
|
Coeur Mining Inc
NYSE:CDE
|
0.049x |
|
Telefonica Brasil SA ADR
NYSE:VIV
|
0.081x |
|
Partners Group Holding AG
SW:PGHN
|
0.271x |
|
Raiffeisen Bank International AG
VI:RBI
|
-0.142x |
|
Shenzhen Inovance Tech
SHE:300124
|
0.025x |
|
Accelink Technologies Co Ltd
SHE:002281
|
0.114x |
|
FUJIFILM HDGS CORP. ADR 1
F:FJIA
|
N/A |
Annual Cash Flow Conversion Efficiency for Roivant Sciences Ltd (2019–2025)
The table below shows the annual cash flow conversion efficiency of Roivant Sciences Ltd from 2019 to 2025. View current stock price of Roivant Sciences Ltd for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-03-31 | $5.19 Billion | $-839.45 Million | -0.162x | -36.37% |
| 2024-03-31 | $6.45 Billion | $-765.27 Million | -0.119x | +77.38% |
| 2023-03-31 | $1.61 Billion | $-843.39 Million | -0.525x | -59.58% |
| 2022-03-31 | $2.06 Billion | $-677.73 Million | -0.329x | -28.73% |
| 2021-03-31 | $2.16 Billion | $-552.14 Million | -0.255x | +29.31% |
| 2020-03-31 | $2.11 Billion | $-761.83 Million | -0.361x | +66.94% |
| 2019-03-31 | $937.30 Million | $-1.02 Billion | -1.093x | -- |
About Roivant Sciences Ltd
Roivant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines and technologies. Its clinical product candidates include IMVT-1402, a fully human monoclonal antibody that targets the neonatal fragment crystallizable receptor for the treatment of graves' disease, difficult-to-treat rheumatoid arthritis, sjögren's disease… Read more